| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |